Neuroplast
PrivateLast Round
Series B
Nov 17, 2021
Total Funding Raised
$15.9M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Neuroplast operates in Healthcare & Life Sciences and is based in Maastricht. Its latest recorded funding round was a Series B round in November 2021.
Neuroplast is a biotechnology company that develops the autologous stem cell platform product Neuro-Cells®, a treatment to combat neurodegeneration resulting from trauma, disease and ageing.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Neuroplast Comparables
Compare Neuroplast with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Regeneration Biomedical, Inc. | 79% | |
| Matricelf Ltd | 77% | |
| Brainstorm Cell Therapeutics Inc. | 77% |
For institutional investors. Book with your work email.
Neuroplast Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Nov 17, 2021 | ||||
| Series A | Feb 19, 2020 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Neuroplast Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| 819 Capital Partners | Series A |
| Brightlands Venture Partners | Series B, Series A |
| Lumana Invest | Series B |
| LIOF | Series B, Series A |
| Netherlands Enterprise Agency | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 17, 2026
Grew 33% QoQ from 9 to 12 employees.
- Apr 25, 2026
Grew 43% QoQ from 7 to 10 employees.
For institutional investors. Book with your work email.
Neuroplast Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Neuroplast's valuation, stock price, and market status.
Is Neuroplast a public or private company?
Neuroplast is a private company.
What is the current stock price of Neuroplast?
Neuroplast is a private company, so its shares have no public market price. Caplight tracks Neuroplast's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Neuroplast worth (valuation)?
Valuation information for Neuroplast is not publicly available.
Can I buy Neuroplast stock?
Neuroplast shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Neuroplast's last funding round?
Neuroplast's most recent funding round was Series B on November 17, 2021.
Who are the main investors in Neuroplast?
Key investors in Neuroplast include Lumana Invest.
Will Neuroplast IPO soon?
No public IPO plans have been announced for Neuroplast.
How can I track Neuroplast secondary market activity?
Caplight tracks bids, offers, and trades in Neuroplast's shares on secondary markets.